About Foresite Capital
Foresite Capital is a venture capital firm founded in 2011. It is primarily based out of New York City, United States. As of Sep 2026, Foresite Capital is an active investor, having invested in 214 companies, with 10 new investments in the last 12 months. It primarily invests in Series B round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to High Tech and Enterprise Applications. Most recently it participated in the $***** Post IPO round of Korsana Overall, Foresite Capital portfolio has seen 7 unicorns, 85 IPOs and 69 acquisitions including key companies like Hims, 10X Genomics and Natera. A lot of funds co-invest with Foresite Capital, with names like Orbimed sharing a substantial percentage of its portfolio. Foresite Capital has team of 27 people including 12 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series B, Series C & 7 more
Portfolio IPOs
Portfolio Acquisitions
Portfolio Unicorns
Deals in last 12 months
Foresite Capital's List of Top Investments
Foresite Capital has a portfolio of 214 companies, including 7 unicorns. Their most notable investments are in Element Biosciences and Pharvaris.Their portfolio spans across United States, United Kingdom, Canada and 6 more locations. They have invested in Life Sciences, High Tech, Enterprise Applications and 7 other sectors, across stages such as Series B, Series C and 7 more. Here is the list of top investments by Foresite Capital:
1. Hims
Online platform offering telehealth services for men's wellness. The company focuses on men's wellness and care, offering treatment options for hair loss, erectile dysfunction, and more.
Key facts about Hims
- Founded Year: 2017
- Location: San Francisco (United States)
- Annual Revenue: $1B+ as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $197M
- Employee Count: 2,090 as on Aug 31, 2026
- Investors: Brentwood Associates, Foresite Capital and 17 Others
- Latest Funding Round: Post IPO, May 08, 2025, $*****
- Highlight: Public
2. 10X Genomics
Developer of single-cell, spatial, and in situ tools for high-resolution biological analysis. The company develops instruments, consumables, and software that enable researchers to profile up to a million cells, map RNA and proteins in tissues, and support multiomics workflows, with products cited in publications.
Key facts about 10X Genomics
- Founded Year: 2012
- Location: Pleasanton (United States)
- Annual Revenue: $500M - $1B as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $243M
- Employee Count: 2,429 as on Jul 31, 2026
- Investors: Sprout Capital Partners, Meritech and 14 Others
- Latest Funding Round: Series D, Jan 07, 2019, $*****
- Highlight: Public
3. Natera
Developer of cell-free DNA testing for oncology, women’s health, and organ health. The test provided by the company inlcude Signatera– a residual disease test (MRD), Altera– tumor genomic profile, Empower– Hereditary cancer test, Prospera Kidney– transplant assessment, Panorama– Noninvasive prenatal testing (NIPT), Anora– Miscarriage Test, and more.
Key facts about Natera
- Founded Year: 2004
- Location: Redwood City (United States)
- Annual Revenue: $1B+ as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $152M
- Employee Count: 5,983 as on Aug 31, 2026
- Investors: Harmony Partners, Bain Capital Life Sciences and 18 Others
- Latest Funding Round: Post IPO, Apr 13, 2020, $*****
- Highlight: Public
4. iRhythm Tech
Provider of cloud-based cardiac rhythm monitoring devices. It provides Zio ambulatory ECG monitor a wearable patch designed to gather beat-to-beat heart data for the diagnosis of cardiac arrhythmias. The device stores data in the patch and is emailed to the iRhythm cloud at the end of the monitoring period. myZio iPhone app is an add-on for the Zio Patch for physicians to make a diagnosis.
Key facts about iRhythm Tech
- Founded Year: 2006
- Location: San Francisco (United States)
- Annual Revenue: $500M - $1B as on Dec 31, 2024
- Stage: Public
- Total Funding till date: $98.9M
- Employee Count: 1,853 as on May 31, 2026
- Investors: Foresite Capital, UNC Kenan-Flagler Private Equity and 12 Others
- Latest Funding Round: Series E, May 22, 2014, $*****
- Highlight: Public
Developer of therapies to treat neurodegenerative diseases. The company's product pipeline includes a small molecule inhibitor of RIP1 kinase to treat Alzheimer's and ALS by regulating inflammatory signaling and affecting glial dysfunction in the brain. Also, provides an LRRK2 inhibitor to treat Parkinson's disease.
Key facts about Denali Therapeutics
- Founded Year: 2015
- Location: San Francisco (United States)
- Annual Revenue: $100M - $500M as on Dec 31, 2023
- Stage: Public
- Total Funding till date: $347M
- Employee Count: 603 as on Jul 31, 2026
- Investors: Foresite Capital, Baillie Gifford and 10 Others
- Latest Funding Round: Post IPO, Feb 27, 2024, $*****
- Highlight: Public
Foresite Capital's Year-on-Year Investment Trends
Foresite Capital has invested in 215 companies over the last 14 years, with an average of 9 new investments annually in the last 10 years. In 2025, it made 9 investments, while as of Sep 2026, it has made 12 investments in this year. Its most recent first time investment was in Khartis Therapeutics and most recent follow-on round was in Korsana.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 7 | 5 | 12 |
2025 | 5 | 4 | 9 |
2024 | 11 | 7 | 18 |
2023 | 3 | 4 | 7 |
2022 | 6 | 8 | 14 |
2021 | 14 | 10 | 24 |
2020 | 21 | 12 | 33 |
2019 | 8 | 6 | 14 |
2018 | 13 | 3 | 16 |
2017 | 5 | 3 | 8 |
Foresite Capital's Investments by Stage
Foresite Capital has made 41 investments in Series B stage with an average round size of $65.9M, 26 investments in Series C stage with an average round size of $115M and 24 investments in Series A stage with an average round size of $87.9M.Stage of entry | No. of Investments |
|---|---|
Series B | 41 |
Series C | 26 |
Series A | 24 |
Post IPO | 10 |
Series D | 8 |
Others | 9 |
Note: We have considered here, only first round of investments
Foresite Capital's Investments by Sector
Foresite Capital has a diverse portfolio, with companies operating in the Life Sciences, High Tech, HealthTech, Enterprise Applications and Sustainability Tech. Notably, it has invested in 194 Tech companies, 184 Enterprise (B2B) companies, 32 Software companies and at least 18 companies focusing on Tech hardware.Sector | No. of Investments |
|---|---|
Life Sciences | 101 |
High Tech | 25 |
HealthTech | 18 |
Enterprise Applications | 15 |
Sustainability Tech | 7 |
Others | 16 |
Note: We have considered here, only first round of investments
Foresite Capital's Investments by Geography
Foresite Capital has made most investments in United States (106), followed by United Kingdom where it has made 6 investments.Country | No. of Investments |
|---|---|
United States | 106 |
United Kingdom | 6 |
Ireland | 2 |
China | 1 |
Israel | 1 |
Others | 1 |
Note: We have considered here, only first round of investments
Foresite Capital's recent investments
Foresite Capital has made 12 investments in 2026 so far. Korsana and Thyme Care are the latest among them.Here are the most recent investments by Foresite Capital:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Sep 10, 2026 | United States | Post IPO | 1563 | [+14] | |
Sep 02, 2026 | United States | Series E | 2035 | [+8] | |
Aug 13, 2026 | United States | Series B | 7176 | ||
Aug 07, 2026 | United States | Series D | 5064 | ||
Aug 05, 2026 | United States | Post IPO | 3906 |
Unicorns in Foresite Capital's Portfolio
Foresite Capital has 7 unicorns in its portfolio - Join Midi, Thyme Care, Element Biosciences and others. The most recent unicorn in their portfolio is Join Midi. It became a unicorn in 2026.Here is a list of unicorns in Foresite Capital's portfolio:
Tracxn Score | Company | Short Description | Founded year | Sector | Location | Company Stage | First Investment/ Acquisition Details |
|---|---|---|---|---|---|---|---|
65 | Provider of a virtual care platform focused on female midlife health | 2021 | Los Altos Hills | Series D | yvivhtg | ||
66 | Provider of home nursing care services | 2020 | Nashville | Series E | hcnqvlz | ||
64 | Developer of benchtop DNA sequencer for research applications | 2017 | San Diego | Series E | bfmytwn | ||
65 | Provider of molecular diagnostics platform by using CRISPR technology | 2017 | Brisbane | Series D | jdz{biw | ||
60 | Provider of home-based diagnostic tests for the detection of various diseases | 2014 | Austin | Funding Raised | utqashq |
IPOs and Publicly Listed companies in Foresite Capital's Portfolio
85 of Foresite Capital's portfolio companies have become public. Latigo Biotherapeutics got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ), in Aug 2026 at marketcap of $1.14B and Parabilis Medicines got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ) at marketcap of $2.33B.Here are Foresite Capital's portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Aug 07, 2026 | Feb 14, 2024 | Series A | 4807 | |
Jun 10, 2026 | Mar 01, 2024 | Series E | 4656 | |
May 08, 2026 | Dec 08, 2021 | Series A | 5604 | |
May 01, 2026 | Oct 18, 2024 | Series B | 3687 | |
Feb 05, 2026 | May 05, 2021 | Series A | 6188 |
Acquired companies in Foresite Capital's Portfolio
69 companies from Foresite Capital's portfolio have been acquired. The most recent acquisition was Kira Pharmaceuticals in Jul 2026 by Jasper Therapeutics for $*****.Here are Foresite Capital's portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Jul 16, 2026 | Jan 07, 2021 | Series B | 3242 | |
Jun 17, 2026 | Apr 04, 2025 | Series A | 1444 | |
May 03, 2026 | Sep 09, 2024 | Series D | 3407 | |
Jan 20, 2026 | Dec 23, 2024 | Post IPO | 9465 | |
Dec 15, 2025 | Feb 27, 2018 | Series B | 8697 |
Team profile of Foresite Capital
Foresite Capital has a team of 27 members including 12 Partners and 3 Principals located in United States. Foresite Capital's team sits on the board of 2 companies.Here is a list of top team members in Foresite Capital:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | - | |||
Partner | San Francisco | |||
Partner | Denver | - | ||
Partner | San Francisco | - | ||
Partner | New York City | - | ||
Partner | San Francisco | - | ||
Partner | New York City | - | ||
Partner | Denver | - | ||
Partner | New York City | - | ||
Partner | - | - | ||
Partner | - | - | - |
Co-investors of Foresite Capital
Over the past 14 years, 918 investors have co-invested in Foresite Capital's portfolio companies. This includes funds and angels.
- Invested before Foresite Capital: HHS, Google Ventures and 364 others have invested in rounds before Foresite Capital. There are 14 companies where HHS has invested before Foresite Capital and 11 companies where Google Ventures has invested before Foresite Capital.
- Top Co-investors of Foresite Capital: 259 investors entered a company along with Foresite Capital. These include investors like Orbimed (19 companies).
- Invested after Foresite Capital: A total of 293 investors have invested in Foresite Capital's portfolio after their investments. Top Investors include RA Capital Management (9 companies), Fidelity Investments (8 companies) and Janus Henderson Investors (8 companies).
Recent News related to Foresite Capital
•
Khartis Therapeutics Raises $50M in Series B FundingFinSMEs•Aug 13, 2026•Nextech Invest, Forge Life Science Partners, Alexandria, Longwood Fund and 1 other
•
Stepful Announces $55M Series C to Scale Its AI-Powered Training Platform Across the Healthcare WorkforceTraining Industry•Jun 08, 2026•Education Impact Fund, Intermountain Healthcare, Stepful, SemperVirens and 5 others
•
Pinnacle raises an $89M series B for its oral peptide programsBioWorld•Mar 26, 2026•Pinnacle Medicines, LAV, Foresite Capital, Logos and 4 others
•
•
•
•
Midi Health Receives $100M Series D RoundMassinvestor•Feb 03, 2026•Join Midi, SemperVirens, Emerson Collective, Advance Venture Partners and 9 others
•
Parabilis gets $305M to conquer 'undruggable' proteins after early successEndpoints•Jan 08, 2026•Parabilis Medicines, Johnson & Johnson, Frazier Life Sciences, Rock Springs Capital and 19 others
•
Aeovian gets $55M for tuberous sclerosis complex, to explore prospects in obesityEndpoints•Dec 16, 2025•Aeovian Pharmaceuticals, Hevolution, Sofinnova Investments, CTI Life Sciences Fund and 7 others
•
